NICE now recommends Esbriet (InterMune) for idiopathic Pulmonary Fibrosis

InterMune submitted additional evidence of benefit after NICE (The National Institute of Health and Clinical Excellence) rejected Esbriet (pirfenidone) as a treatment for patients with idiopathic Pulmonary Fibrosis.InterMune agreed to revise its patient access scheme.

NICE now recommends Esbriet for use in patients who have a Forced Vital (Lung) Capacity of between 50% and 80% predicted.The cost was expected to be around �24000 per QALY for each patient.